Olaratumab Plus Doxorubicin in Advanced Soft Tissue Sarcoma

Video

William D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

This study looked at the combination of olaratumab and doxorubicin compared with doxorubicin alone as treatment for patients with advanced soft tissue sarcoma. The combination showed a 50% improvement in progression-free survival and an 11.8-month increase in overall survival.

Based on this study, the monoclonal antibody is being investigated in an ongoing phase III study and has received an FDA Breakthrough Therapy Designation.

Read more about the study >>

Recent Videos
Related Content
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl
November 15th 2024
Article

Read More

Breaking New Ground in Synovial Sarcoma: Choy on the FDA Approval of Afami-cel

Breaking New Ground in Synovial Sarcoma: Choy on the FDA Approval of Afami-cel

Jordyn Sava;Edwin Choy, MD
August 15th 2024
Podcast

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

Listen

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More

Advancing the Treatment of Alveolar Soft Part Sarcoma

Advancing the Treatment of Alveolar Soft Part Sarcoma

Nichole Tucker;Alice P. Chen, MD
April 26th 2023
Podcast

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

Listen

Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment

Exploring the Benefits of Nab-Sirolimus in Advanced PEComa Treatment

Jordyn Sava
October 29th 2024
Article

In an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with advanced PEComa.

Read More

Bringing Bispecific Antibody Therapy to Community Oncology Centers

Bringing Bispecific Antibody Therapy to Community Oncology Centers

Jordyn Sava
October 11th 2024
Article

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

Read More